Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

AstraZeneca Stays Hopeful About Ultomiris Despite Initial Conversion Difficulties

Sales of Soliris Successor Stumble

Executive Summary

AstraZeneca is touting Ultomiris’ future potential in neurological conditions as it struggles to convert patients from predecessor Soliris in one of its indications. 

You may also be interested in...



AstraZeneca Clears Ultomiris Overhang With Patent Settlement

The company will pay Chugai $775m to settle a patent dispute related to the complement 5 inhibitor Ultomiris, which it acquired from Alexion.

Casualty Of Change? Innovent/Lilly’s Chinese PD-1 Inhibitor Sintilimab Falls Hard At US FDA Panel

Advisory committee says additional trials needed to demonstrate applicability of ORIENT-11 results to US population; in opting to seek approval only with Chinese data, Innovent said it relied on 2019 comments by FDA’s Richard Pazdur, but the oncology center head said therapeutic and societal changes have caused an evolution in the agency’s thinking.

AstraZeneca Doubles Down On Amyloidosis With Neurimmune Alliance

The UK major is paying $30m upfront and up to an extra $730m for the rights to Neurimmune’s NI006, which is in Phase Ib trials for the treatment of transthyretin amyloid cardiomyopathy.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC145878

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel